Cardiff Oncology

• NCT05383196

  Collaborator, Phase 1/2, Active, not recruiting, 50 people, 20 May 2022

• NCT03414034

  Phase 2, Completed, 72 people, 29 Jan 2018

• NCT03303339

  Phase 1/2, Completed, 72 people, 6 Oct 2017

• Association of sodium-glucose co-transport protein 2 inhibitor use with clinical outcomes in patients receiving immune checkpoint inhibitors: a pan-tumor propensity-matched analysis

  Grants or research support, 6 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov